Live
FierceBiotechFDA Commissioner Marty Makary to resign, capping turbulent tenure: reportFierceBiotechKyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysisClinical OMICsLow‑Dose Digoxin Shows Benefit in Heart Failure TreatmentClinical OMICsAntibody Promotes Nerve Regeneration in Spinal Cord Injury PatientsClinical OMICsSingle Procedure Reduces Colorectal Cancer Risk Decades Later10x Genomics News10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property ReviewClinical OMICsFirst Clinical Trial for a GLP-1 Gene Therapy Greenlit in EuropeBioPharma DiveFDA chief Marty Makary resigns from agency, ending tumultuous tenureEndpoints NewsEU reaches provisional deal on Critical Medicines ActEndpoints NewsFDA Commissioner Makary to resign, source saysEndpoints NewsIran war disruptions begin to emerge upstream of the pharma supply chainFierceBiotechCharles River debuts AI diagnostic tool to cut down pathology timelines
Lonza News Mar 28, 2026

Lonza Group AG Stock: A Key Player in Biopharma Manufacturing for North American Investors - AD HOC NEWS

Lonza Group AG Stock: A Key Player in Biopharma Manufacturing for North American Investors - AD HOC NEWS

Body unavailable. Use the original source.